Context Therapeutics Inc

+0.24 (+18.90%)
7:40:59 PM EDT: $1.44 -0.07 (-4.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Context Therapeutics Inc Stock, NASDAQ:CNTX

2001 Market Street, Unit 15, Philadelphia, Pennsylvania 19103
Phone: +
Number of Employees: 9


Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.